Aditxt, Inc. (NASDAQ: ADTX)

Accelerating Innovation

Safe Harbor Statement & Disclaimers

This presentation contains forward-looking statements that are subject to many risk and uncertainties. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, our ongoing and planned product development; our intellectual property position; our ability to develop commercial functions; expectations regarding project launch and revenue; our results of operations, cash needs, spending, financial condition, liquidity, prospects, growth and strategies; the industry in which we operate; and the trends that may affect the industry or us. Although we believe we have a reasonable basis for each forward-looking statement, we caution you that forward looking statements are not guarantees of future performance.

Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, as well as those risks more fully discussed in the section entitled "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2021, that was filed with the U.S. Securities and Exchange Commission on March 25, 2021 as well as discussions of potential risk, uncertainties, and other important factors in the Company's subsequent filings with the U.S. Securities and Exchange Commission. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

This Presentation includes certain projections and forward-looking statements provided by the Company, including with respect to the anticipated future performance of the Company, and our ability to develop and commercialize products and obtain regulatory approvals. Such projections and forward-looking statements reflect various assumptions of management, and are subject to significant business, regulatory, economic and competitive uncertainties and contingencies, many of which are beyond the control of the Company. Accordingly, there can be no assurance that such projections or forward-looking statements will be realized. Actual results may vary from anticipated results and such variations may be material. Therefore, you should not rely on any of these projections or forward-looking statements. Important factors that could cause our actual results to differ materially from those indicated in the projections or forward-looking statements include, among others: (i) risks associated with the regulatory approval process; (ii) our ability to enter strategic relationships for development or commercialization of our products; (iii) patents may not issue from our patent applications, patents that have issued may not be enforceable, or additional intellectual property licenses from third parties may be required; (iv) our ability to obtain sufficient financing; and (v) our ability to consummate on terms that are favorable to us or at all any potential strategic

transactions. Any projection or forward-looking statement made by us in this Presentation is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to update any projection or forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Beyond Genome Sequencing…

Immune Monitoring and Reprogramming will lead to a new era of precision medicine

The New Age of Immunity

AMRO ALBANNA
Co-founder, Chairman and CEO of Aditxt, Inc.

Our Business Model

We Develop, Operate, Commercialize, and Monetize promising biotechnologies in the field of immunology

Shareholders

Monetize

1. Innovate

2. Operate

3. Commercialize

The company to deliver

Locations

Richmond, VA
Corporate Headquarters

Silicon Valley, CA
Innovation and Product Development

New York City, NY
Business and Corporate Functions

Current Programs

Richmond, VA
AditxtScore™

Berlin, Germany
Adimune™

| Innovation	Operation	Commercialization	Corporate	CEO and Board
Shahrokh Shabahang, MS, PhD Co-founder, Chief Innovation Officer, Board Member	**Rowena Albanna** Chief Operating Officer	**Joachim-Friedrich Kapp, MD, PhD** Head of Adimune™	**Corinne Pankovcin** President	**Amro Albanna** Co-founder, CEO, Chairman of the Board of Directors
Ge Chen, M.D. Senior Vice President, Preclinical Research & Discovery	**Rodger Paxton** Director of Information Technology	**Anthony Voorhies** Head of AditxtScore	**Thomas J. Farley, CPA** Chief Financial Officer	**Brian Brady, CFA** Independent Director
Dolly Tyan, PhD, D(ABHI)	**Simon Sansano** Laboratory Compliance Manager	**Joseph P. McConnell, PhD, DABCC, FAACC** SVP Laboratory Science, AditxtScore	**Matthew Shatzkes, Esq.** Chief Legal Officer, General Counsel	**Namvar Kiaie** Independent Director
		Anastasia Katany, D.O. ABFM, FAARFM, ABAARM	**Jennifer Lee** Vice President of Human Resources	**Jeffrey Runge, M.D** Independent Director

Aditxt™
Immune Health

—

Asset #1:
AditxtScore™

Opportunity

We must monitor our immune status to make more informed and timely health decision

- Everyone's immune system is unique and responds differently to viruses, bacterial antigens, peptides, drugs, bone marrow, solid organ transplants and cancer

- By measuring and monitoring each individual's immune system, it unlocks a new universe of maintaining and treating our immune health. This is precision made possible.

AditxtScore™: Immune Monitoring Platform

- A proprietary platform for comprehensive profiles of any individual's immune system – monitors reactions to viruses, bacteria, allergens and transplanted organs.

- Can anticipate attacks on the body and determine potential responses, guiding a plan to manage the condition or neutralize the pathogen

- Initial technology was licensed from Stanford University. It encompasses methods, systems and kits for detection and measurement of specific immune responses.

- AditxtScore™ technologies are protected by two patent families

- Substantial know-how and trade secrets in development and commercialization

AditxtScore™ Cellular Immunity Assessment Evaluation of memory B cell response (v. 2.0)

- Can detect 100 different targets

- Four-hour assay

- Sensitivity = 1 / 106 cells

Chen G, Liu H, Tyan D. FlowSpot: Real time prediction and monitoring of cellular immune profiles for responses to pathogens, vaccines, therapeutics, and transplantation. Manuscript submitted for publication.

#1 Innovation

AditxtScore for COVID-19

No exposure

Natural exposure

Vaccine-induced

#1 Innovation

AditxtScore™ for Type 1 Diabetes in Development

Early Detection of Auto-antibodies

AditxtScore™ for T1D

- Detection of auto-antibodies to all 4 beta cell antigens in a single multiplex assay
- Monitoring of disease progression
- Monitoring of response to therapy

Nature Reviews | Disease Primers

	Stage 1	Stage 2	Stage 3
ß-cell autoimmunity (with the prescence of autoantibodies	Present*	Present	Present
ß-cell loss	Present	Present	Present
Dysglycaemia	Absent	Hyperglycaemia	Hyperglycaemia
Symptoms	Absent	Absent	Present

Functional ß-cell mass (%)

100

75

50

25

0

Variable genetic and environmental risk for T1DM

Stage 1 Patients

Stage 2 Patients

Newly Diagnosed/ Early Stage 3 Patients

Presymptomatic T1DM

Symptomatic T1DM

Disease progression

Aditxt
Immune Health

#1 Innovation

AditxtScore™ Potential Applications

Immune System
Organ Failure
Infectious Diseases
Disease Susceptibility

Brain
Depression
Anxiety
Brain Fog
Sleep Problems

Bones and Joints
Rheumatoid Arthritis
Fibromyalgia
Osteoporosis

AditxtScore™
Antibodies
Cellular...

Thyroid
Hashimotos
Hypothyroidism
Graves

Hormone Imbalances
Fatigue
Hair Loss
Weight Gain or Loss
Sugar/Salt Cravings

Cardio-metabolic
Heart Disease
Diabetes
Metabolic Syndrome

#2 Operation

Scaling Up for Millions of Tests

High-capacity, CLIA-certified AditxtScore™ immune monitoring center in Richmond, Virginia

Introduced in a joint press conference including Virginia Governor Ralph Northam and Richmond Mayor Levar Stoney

Potential to scale to process up to 10 million AditxtScores™ annually

Active Sales Channels

#3 Commercialization

Collectors
(insurance with service fees)

Distributors
(client bill)

Employers
(client bill)

Physicians
(insurance & client bill)

Referring Labs
(client bill)

Draw Stations
(client bill)

#3 Commercialization

- For the quarter ended March 31, 2022 Aditxt recognized $210,279 of revenue compared to $105,034 in the year ended December 31, 2022.

Aditxt Revenue

	Q1 2021	Q2 2021	Q3 2021	Q4 2021	Q1 2022

$350,000
$300,000
$250,000
$200,000
$150,000
$100,000
$50,000
$-

$210,279
$105,034

Aditxt™
Immune Health

—

Asset #2:

Adimune™

Opportunity

Modulating the immune system to address autoimmunity, organ rejection, and allergies

Immune Modulation:
Our Platform

Technologies protected by 7 patent families:

- 8 U.S. patents, 4 U.S. pending applications, 86 foreign patents, and 14 foreign pending applications (EU, Australia, Canada, Japan, China, India, Hong Kong)

Patents categorized into 3 groups

- Autoimmune diseases and type 1 diabetes
- Prevention of immune activation
- Delivery systems for antigens

We also possess and in-license substantial know-how and trade secrets for development and commercialization, including related manufacturing processes and technologies.

ENCODES TARGET PROTEIN

ENCODES PRO-APOPTOTIC PROTEIN

Plasmid DNA inducing tolerance-inducing target protein

Plasmid DNA inducing natural 'programmed' cell death

#1 Innovation

Psoriasis

What is it?

Caused when the immune system attacks skin cells, triggering fast production of replacements leading to patches of build-up, psoriasis is often distressing and uncomfortable. It can also reduce life expectancy.

Our treatment

Aditxt's solution aims to prevent the immune system attacks, dealing with the cause of skin cell build-ups at their root. Our treatment reduced skin thickening by 69% and scaling by 38% over a 10-day study period in an established psoriasis model.

Increase in Skin Thickness
Psoriasis Induced

Change in thickness (mm)

Increase in Scaling
Psoriasis Induced

Scaling Score (range=0-4)

#1 Innovation

Type I Diabetes

What is it?

The condition is triggered by the immune system attacking insulin-producing cells in the pancreas. As insulin allows glucose to move from our blood into our cells to produce energy, diabetes creates a build up of sugar in the blood and deprives the cells. It decreases life expectancy and can damage the heart, kidneys, eyes and feet.

Our treatment

Aditxt's solution aims to stop the precise immune system malfunction in its tracks, allowing the production of insulin. Immunotherapy that achieves this would be the first permanent cure for the disease. In initial trials our treatment restores insulin production and reverses hyperglycemia.

ADi Tx of NOD mice at >200 mg/dL

#1 Innovation

Skin Allografts

What is it?

The grafting of skin from one person to another, the donor often being dead, is often considered the best treatment for wound coverage, especially for victims with extensive burns. However, it is not permanent, and rejection is inevitable.

Our treatment

Aditxt's solution aims to increase the graft's longevity by a factor of three, improving each patient's quality of life and reducing the number of medical procedures required.

Skin Allograft Transplantation

Aditxt treatment

Allograft lasts 58 days on average
3-fold increase in logevity
of the skin allograft

58 days

Immunosuppression alone

Allograft lost
in 21 days
on average

21 days

#2 Operation

Indication	H1 2021	H2 2021	H2 2022	2023
Psoriasis	IND-enabling studies			Clinical trials
Type 1 Diabetes	IND-enabling studies			Clinical trials
Skin Allograft Transplantation	Nonclinical studies			Clinical trials
Multiple Sclerosis	Construct	Nonclinical studies		IND-enabling studies

#3 Commercialization

Pre-Phase III Pharma/Biotech to Pharma/Biotech Deal Count Last 5 years

Significant opportunity in pharma backed indications

Significant upside potential in low saturated indication

Notable Recent Licensing Transactions

Deal Date	Licensor	Licensee	Phase of Develop-ment	Indication(s)	Deal Type	Upfront Payment (M)	Milestone Payment (M)	Total Deal Value (M)
13-Nov-2019	Exicure	Allergan	Discovery	Alopecia	License – Collaboration (option)	$25	$725	$770
30-Oct-2019	Pandion Therapeutics	Astellas Pharma	Discovery	Type 1 Diabetes	License – Collaboration	$45	$750	$795
29-Oct-2018	Denali Therapeutics	Sanofi Genzyme	Phase 1 Clinical	Psoriasis and other CNS indications	License – Collaboration (option)	$125	$1,095	$1,220
02-Dec-2016	Exicure	Purdue Pharma	Phase 1 Clinical	Psoriasis	License – Collaboration (option)	$10	$777	$787
02-Jun-2015	Anokion	Astellas Pharma	Discovery	Type 1 Diabetes and Celiac disease	License – Collaboration	Undisclosed	Undisclosed	$760

Aditxt™
Immune Health

—

Asset #3:

Cellvera Revenue Sharing

Summary

Program	2020	2021	2022	2023
AditxtScore		Development	Operation	Commercialization	Monetization
Adimune	Development			Operation	Commercialization Monetization
Cellvera		Development, Operation and Commercialization (by Cellvera)			Monetization

Ticker	Market Cap	Share Price[1]	Shares Outstanding[2]	Avg. Daily Trading Volume (90 day) [1]
ADTX	~$9 M	~$0.19	~48 M	~5M

1. Source: Yahoo! Finance: As of July 11, 2022.
2. Source: Aditxt March 31, 2022 form 10-Q.

Contacts

Aditxt, Inc. (Aditxt™)

IR@aditxt.com

737 N. Fifth Street, Suite 200
Richmond, VA 23219

Main: 650-870-1200

THE AGE
OF IMMUNITY

APPENDIX: Sources

https://www.alliedmarketresearch.com/autoimmune-disease-therapeutics-market

https://www.bchttps://www.alliedmarketresearch.com/allergy-treatment-market#:~:text=The%20global%20allergy%20treatment%20market,6.3%25%20from%202018%20to%202025.cresearch.com/market-research/pharmaceuticals/infectious-disease-treatments-markets-report.htm

https://www.alliedmarketresearch.com/allergy-treatment-market#:~:text=The%20global%20allergy%20treatment%20market,6.3%25%20from%202018%20to%202025

https://www.grandviewresearch.com/industry-analysis/transplantation-market

https://www.grandviewresearch.com/industry-analysis/central-nervous-system-cns-therapeutic-market#:~:text=The%20global%20CNS%20therapeutic%20market,USD%20124.0%20billion%20in%202021

https://www.fortunebusinessinsights.com/dermatology-drugs-market-104432

https://finance.yahoo.com/quote/ADTX/